Sugi Predict

Sugi Predict / Compounds / SCHEMBL10115664

SCHEMBL10115664

SCHEMBL10115664

CC(C)(C)S(=O)(=O)NC1CCN(C(=O)Nc2ccc(N3CC=CC3)cc2)CC1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.50
▸ NPSR1 Q6W5P4 1/20 0.50
▸ CA12 O43570 7/20 0.48
▸ CA2 P00918 7/20 0.48
▸ CA9 Q16790 7/20 0.48
▸ CA1 P00915 6/20 0.48
▸ CCR8 P51685 1/20 0.44
▸ POLB P06746 1/20 0.44
▸ ALOX15 P16050 1/20 0.44
▸ HPGDS O60760 1/20 0.43
▸ ME2 P23368 1/20 0.43
▸ ME1 P48163 1/20 0.43
▸ ME3 Q16798 1/20 0.43
▸ PTPN7 P35236 1/20 0.43
▸ CTDSP1 Q9GZU7 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ NAMPT P43490 3/20 0.43
▸ MAPT P10636 2/20 0.43
▸ KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10115579 0.88 ALDH1A1 (0.55) LMNANPSR1CCR8TDP1
SCHEMBL10115611 0.88 CA12 (0.48) LMNANPSR1CA12CA2CA9
SCHEMBL10115604 0.88 NAMPT (0.56) LMNANPSR1CA12CA2CA9
SCHEMBL10115617 0.87 LMNA (0.53) LMNANPSR1CA12CA2CA9
SCHEMBL10115527 0.87 LMNA (0.66) LMNANPSR1POLBALOX15CTDSP1
SCHEMBL12882021 0.87 LMNA (0.53) LMNANPSR1CA12CA2CA9
SCHEMBL10133815 0.87 LMNA (0.47) LMNANPSR1CA12CA2CA9
SCHEMBL10115589 0.87 LMNA (0.47) LMNANPSR1CA12CA2CA9
SCHEMBL10115590 0.87 LMNA (0.47) LMNANPSR1CA12CA2CA9
SCHEMBL10133805 0.87 LMNA (0.47) LMNANPSR1CA12CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 — — US disclosed
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 — — US disclosed
US-20110039802-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2011-02-17 — — US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 — — US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 — — US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 — — US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 — — US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 — — US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 — — US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 — — US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015762-A1 NPY Y5 antagonist NPY5R, NPY1R, NPY2R LMNA 1925/4885NPSR1 7/4885CA12 1882/4885
US-20100292500-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R LMNA 2068/4885NPSR1 8/4885CA12 1954/4885
US-20110039802-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R LMNA 1857/4885NPSR1 7/4885CA12 2123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.